Literature DB >> 24721393

Development of a qPCR method to rapidly assess the function of NKT cells.

Silke Sohn1, Irina Tiper1, Emily Japp2, Wenji Sun1, Katherine Tkaczuk2, Tonya J Webb3.   

Abstract

INTRODUCTION: NKT cells comprise a rare, but important subset of T cells which account for ~0.2% of the total circulating T cell population. NKT cells are known to have anti-tumor functions and rapidly produce high levels of cytokines following activation. Several clinical trials have sought to exploit the effector functions of NKT cells. While some studies have shown promise, NKT cells are approximately 50% lower in cancer patients compared to healthy donors of the same age and gender, thus limiting their therapeutic efficacy. These studies indicate that baseline levels of activation should be assessed before initiating an NKT cell based immunotherapeutic strategy. AIM: The goal of this study was to develop a sensitive method to rapidly assess NKT cell function.
METHODS: We utilized artificial antigen presenting cells in combination with qPCR in order to determine NKT cell function in peripheral blood mononuclear cells from healthy donors and breast cancer patients.
RESULTS: We found that NKT cell activation can be detected by qPCR, but not by ELISA, in healthy donors as well as in breast cancer patients following four hour stimulation.
CONCLUSION: This method utilizing CD1d-expressing aAPCs will enhance our knowledge of NKT cell biology and could potentially be used as a novel tool in adoptive immunotherapeutic strategies.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD1d; NKT cells; aAPCs

Mesh:

Substances:

Year:  2014        PMID: 24721393      PMCID: PMC4073584          DOI: 10.1016/j.jim.2014.03.026

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  45 in total

1.  Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up.

Authors:  Famke L Schneiders; Renée C G de Bruin; Alfons J M van den Eertwegh; Rik J Scheper; C René Leemans; Ruud H Brakenhoff; Johannes A Langendijk; Henk M W Verheul; Tanja D de Gruijl; Johan W Molling; Hans J van der Vliet
Journal:  J Clin Oncol       Date:  2012-01-17       Impact factor: 44.544

2.  Glycolipid antigen processing for presentation by CD1d molecules.

Authors:  T I Prigozy; O Naidenko; P Qasba; D Elewaut; L Brossay; A Khurana; T Natori; Y Koezuka; A Kulkarni; M Kronenberg
Journal:  Science       Date:  2001-01-26       Impact factor: 47.728

Review 3.  Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions.

Authors:  Patrick J Brennan; Manfred Brigl; Michael B Brenner
Journal:  Nat Rev Immunol       Date:  2013-01-21       Impact factor: 53.106

Review 4.  iNKT cells: innate lymphocytes with a diverse response.

Authors:  Marta Monteiro; Luis Graca
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

Review 5.  Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.

Authors:  Wenji Sun; Priyanka B Subrahmanyam; James E East; Tonya J Webb
Journal:  J Interferon Cytokine Res       Date:  2012-10-10       Impact factor: 2.607

6.  Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells.

Authors:  T Kawano; T Nakayama; N Kamada; Y Kaneko; M Harada; N Ogura; Y Akutsu; S Motohashi; T Iizasa; H Endo; T Fujisawa; H Shinkai; M Taniguchi
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

7.  Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients.

Authors:  Shinichiro Motohashi; Seiichiro Kobayashi; Toshihiro Ito; Kumiko K Magara; Osamu Mikuni; Noriaki Kamada; Toshihiko Iizasa; Toshinori Nakayama; Takehiko Fujisawa; Masaru Taniguchi
Journal:  Int J Cancer       Date:  2002-11-10       Impact factor: 7.396

8.  Loss of IFN-gamma production by invariant NK T cells in advanced cancer.

Authors:  S M Tahir; O Cheng; A Shaulov; Y Koezuka; G J Bubley; S B Wilson; S P Balk; M A Exley
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

9.  Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy.

Authors:  Z Illés; T Kondo; J Newcombe; N Oka; T Tabira; T Yamamura
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

Review 10.  Natural killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions.

Authors:  Avadhesh Kumar Singh; Poonam Gaur; Satya N Das
Journal:  Hum Immunol       Date:  2013-12-25       Impact factor: 2.850

View more
  1 in total

Review 1.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.